menu
Investors & Media

Press Releases

Press Releases

Keyword Search

Sep 23, 2022
Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia
Sep 07, 2022
Ionis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis
Aug 30, 2022
Ionis to present at upcoming investor conferences
Aug 09, 2022
Ionis reports second quarter financial results and recent business achievements
Jul 28, 2022
Ionis announces positive topline results from Phase 2b clinical study of fesomersen, a potential novel anti-thrombotic treatment
Jul 27, 2022
Ionis to hold second quarter 2022 financial results webcast
Jul 26, 2022
Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS
Jul 20, 2022
Ionis announces enrollment completion of Phase 3 Lp(a) HORIZON cardiovascular outcomes study of pelacarsen
Jul 13, 2022
Ionis to participate in virtual fireside chat at H.C. Wainwright 1st Annual Hereditary Angioedema Conference
Jul 11, 2022
Ionis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study
Jun 25, 2022
Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™
Jun 21, 2022
Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
Jun 13, 2022
Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA
Jun 03, 2022
Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
May 12, 2022
Ionis to present at RBC Capital Markets Global Healthcare Conference
May 04, 2022
Ionis reports first quarter financial results and recent business achievements
May 02, 2022
Ionis to host 2022 virtual Annual Meeting of Stockholders
Apr 20, 2022
Ionis to hold first quarter 2022 financial results webcast
Apr 04, 2022
Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session
Mar 28, 2022
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Mar 21, 2022
Ionis to present at upcoming investor conferences
Mar 16, 2022
Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine
Mar 07, 2022
Ionis calls for applications for Janice Wiesman Young Investigator Grant Program
Mar 01, 2022
Ionis to present at the Cowen Annual Health Care Conference
Feb 24, 2022
Ionis reports fourth quarter and full year 2021 financial results and recent business achievements
Feb 10, 2022
Ionis to hold full year 2021 financial results webcast
Jan 31, 2022
Pfizer and Ionis announce discontinuation of vupanorsen clinical development program
Jan 24, 2022
Ionis announces eplontersen receives orphan drug designation from U.S. FDA
Jan 19, 2022
Ionis strengthens leadership team with appointments of Joseph Baroldi as chief business officer and Eric Bastings, M.D., as vice president, development strategy
Jan 18, 2022
Ionis' partner to evaluate tominersen for Huntington's disease in new Phase 2 trial
Jan 05, 2022
Ionis to present at 40th Annual J.P. Morgan Healthcare conference
Jan 04, 2022
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
Load More »